tetano
Editor, Senior Moderator
Med Clin (Barc). 2019 May 3. pii: S0025-7753(19)30130-7. doi: 10.1016/j.medcli.2019.02.003. [Epub ahead of print]
[h=1]Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study.[/h] [Article in English, Spanish]
Richi P[SUP]1[/SUP], Mart?n MD[SUP]2[/SUP], Nav?o MT[SUP]3[/SUP], Gonz?lez-Hombrado L[SUP]4[/SUP], Salido M[SUP]5[/SUP], Llorente J[SUP]6[/SUP], Thuissard-Vasallo I[SUP]7[/SUP], Alcocer P[SUP]8[/SUP], Saa-Requejo CM[SUP]9[/SUP], Jim?nez-Diaz A[SUP]10[/SUP], Cebri?n L[SUP]3[/SUP], Lojo L[SUP]3[/SUP], Garc?a-Castro M[SUP]4[/SUP], Sanz-Rosa D[SUP]7[/SUP], Castro P[SUP]5[/SUP], Fern?ndez-Rodr?guez S[SUP]11[/SUP], Mart?nez de Aramayona MJ[SUP]11[/SUP], Steiner M[SUP]10[/SUP], Cobo T[SUP]10[/SUP], Garc?a-Fern?ndez C[SUP]9[/SUP], Fern?ndez-Castro M[SUP]10[/SUP], Illera ?[SUP]10[/SUP], Valverde R[SUP]12[/SUP], Mu?oz-Fern?ndez S[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND AND OBJECTIVES:[/h] Influenza vaccine is recommended for patients with autoimmune inflammatory rheumatic diseases who receive biological therapy. To evaluate if biological therapy impairs immunization after seasonal influenza vaccine.
[h=4]MATERIAL AND METHODS:[/h] Patients with inflammatory arthopathies, psoriasis, inflammatory bowel disease or connective tissue diseases who were receiving or were going to initiate biological therapy were included and vaccinated during 2014-2015 influenza season. ELISA was used to measure influenza antigen A and B antibodies, before and after vaccination. Demographic parameters, diagnosis and kind of treatment were recorded and their influence on the final serological status against influenza was studied.
[h=4]RESULTS:[/h] 253 subjects were analyzed. After vaccination, 77% of participants presented detectable antibodies against antigen A and 50.6% of them had detectable antibodies against antigen B. Final seropositivity rate against antigen B antibodies increased from baseline (50.6% vs 43.5%, p<0.001). Anti-TNF drugs were associated with better response and rituximab with the worst (79.2% vs 55.0% for final seropositivity against antigen A, p=0.020). Vaccine response in the rituximab group tended to improve when the interval between the drug administration and the vaccination was at least 12 weeks (seropositivity rate 80.0% in those with the longer interval vs 25.0% in the other group, p=0.054).
[h=4]CONCLUSIONS:[/h] Among the patients on biological therapy vaccinated against influenza, anti-TNF therapy was identified as a predictive factor of final seropositivity. Rituximab presented a lower rate of final seropositivity, which could be increased with an accurate administration schedule.
Copyright ? 2019 Elsevier Espa?a, S.L.U. All rights reserved.
[h=4]KEYWORDS:[/h] Anti-TNF; Autoimmune inflammatory diseases; Biological therapy; Enfermedades inflamatorias autoinmunes; Influenza vaccine; Rituximab; Terapia biol?gica; Vacuna contra la gripe
PMID: 31060878 DOI: 10.1016/j.medcli.2019.02.003
[h=1]Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study.[/h] [Article in English, Spanish]
Richi P[SUP]1[/SUP], Mart?n MD[SUP]2[/SUP], Nav?o MT[SUP]3[/SUP], Gonz?lez-Hombrado L[SUP]4[/SUP], Salido M[SUP]5[/SUP], Llorente J[SUP]6[/SUP], Thuissard-Vasallo I[SUP]7[/SUP], Alcocer P[SUP]8[/SUP], Saa-Requejo CM[SUP]9[/SUP], Jim?nez-Diaz A[SUP]10[/SUP], Cebri?n L[SUP]3[/SUP], Lojo L[SUP]3[/SUP], Garc?a-Castro M[SUP]4[/SUP], Sanz-Rosa D[SUP]7[/SUP], Castro P[SUP]5[/SUP], Fern?ndez-Rodr?guez S[SUP]11[/SUP], Mart?nez de Aramayona MJ[SUP]11[/SUP], Steiner M[SUP]10[/SUP], Cobo T[SUP]10[/SUP], Garc?a-Fern?ndez C[SUP]9[/SUP], Fern?ndez-Castro M[SUP]10[/SUP], Illera ?[SUP]10[/SUP], Valverde R[SUP]12[/SUP], Mu?oz-Fern?ndez S[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND AND OBJECTIVES:[/h] Influenza vaccine is recommended for patients with autoimmune inflammatory rheumatic diseases who receive biological therapy. To evaluate if biological therapy impairs immunization after seasonal influenza vaccine.
[h=4]MATERIAL AND METHODS:[/h] Patients with inflammatory arthopathies, psoriasis, inflammatory bowel disease or connective tissue diseases who were receiving or were going to initiate biological therapy were included and vaccinated during 2014-2015 influenza season. ELISA was used to measure influenza antigen A and B antibodies, before and after vaccination. Demographic parameters, diagnosis and kind of treatment were recorded and their influence on the final serological status against influenza was studied.
[h=4]RESULTS:[/h] 253 subjects were analyzed. After vaccination, 77% of participants presented detectable antibodies against antigen A and 50.6% of them had detectable antibodies against antigen B. Final seropositivity rate against antigen B antibodies increased from baseline (50.6% vs 43.5%, p<0.001). Anti-TNF drugs were associated with better response and rituximab with the worst (79.2% vs 55.0% for final seropositivity against antigen A, p=0.020). Vaccine response in the rituximab group tended to improve when the interval between the drug administration and the vaccination was at least 12 weeks (seropositivity rate 80.0% in those with the longer interval vs 25.0% in the other group, p=0.054).
[h=4]CONCLUSIONS:[/h] Among the patients on biological therapy vaccinated against influenza, anti-TNF therapy was identified as a predictive factor of final seropositivity. Rituximab presented a lower rate of final seropositivity, which could be increased with an accurate administration schedule.
Copyright ? 2019 Elsevier Espa?a, S.L.U. All rights reserved.
[h=4]KEYWORDS:[/h] Anti-TNF; Autoimmune inflammatory diseases; Biological therapy; Enfermedades inflamatorias autoinmunes; Influenza vaccine; Rituximab; Terapia biol?gica; Vacuna contra la gripe
PMID: 31060878 DOI: 10.1016/j.medcli.2019.02.003